Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study.
We treated 20 adult patients with a (188) Re-labeled anti-CD66 antibody (mean marrow dose 13.3 Gy) prior to allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia or advanced chronic myeloid leukemia. The intensified conditioning was not associated with increased non-relapse mortality. No reduction in the incidence of relapse was observed in the context of a T-cell depleted graft (4-year overall survival: 29%).
Zenz
Thorsten
T
Glatting
Gerhard
G
Schlenk
Richard F
RF
Buchmann
Inga
I
Döhner
Hartmut
H
Reske
Sven N
SN
Bunjes
Donald
D
D000328:Adult; D015703:Antigens, CD / Q000276:immunology; D001853:Bone Marrow / Q000528:radiation effects; D015815:Cell Adhesion Molecules / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage*; D007938:Leukemia / Q000628:therapy*; D008875:Middle Aged; D011868:Radioisotopes / Q000627:therapeutic use; D012211:Rhenium / Q000627:therapeutic use; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous
D015703:Antigens, CD; C069847:CD66 antigens; D015815:Cell Adhesion Molecules; D018796:Immunoconjugates; D011868:Radioisotopes; D012211:Rhenium